close

Enter

Log in using OpenID

Triple Negative Breast Cancer Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2029

embed
The triple negative breast cancer treatment market is forecasted to value over US$ 820 Million by 2029 end and register a CAGR of over 4.5% from 2019 to 2029. Rising advancements in research related to cancer have led to new drugs being introduced t
Triple Negative Breast Cancer Treatment Market Global Trends, Market Share,
Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2029
The triple negative breast cancer treatment market is forecasted to value over US$
820 Million by 2029 end and register a CAGR of over 4.5% from 2019 to 2029.
Rising advancements in research related to cancer have led to new drugs being
introduced to diagnose and treat cancer. The entrance of new drugs and treatments
are aimed at improving the treatment rate against triple-negative breast cancer.
Latest clinical efforts are being targeted towards molecular characterization stage of
triple-negative breast cancer across rising remedial targets like androgen receptors,
PARP1, and non- receptor & receptor tyrosine kinases.
Based on drug type the market is segmented into doxorubicin, cyclophosphamide,
paclitaxel, docetaxel, cisplatin/carboplatin, and others. Doxorubicin is a
chemotherapy drug used to treat acute lymphocytic leukemia, breast cancer, and
bladder cancer. It slows down and stops the growth of the cancer cells. An increasing
number of collaborations and partnerships with clinical trials is creating a vast
demand for doxorubicin. Doxorubicin can also interact with cyclophosphamide and
paclitaxel. Paclitaxel is vastly used for the treatment of ovarian cancer and AIDSrelated Kaposi's sarcoma. Based on the distribution channel, the market is bifurcated
into hospital pharmacies and speciality cancer clinics. Speciality cancer clinics are the
biggest end users owing to the easy availability of facilities.
These latest actions are expected to boost the growth of the triple-negative breast
cancer treatment market. Development of generics remains a lucrative area for the
market. The growing need for effective cancer management and more efficient drugs
is expanding the size of the market. The availability of biosimilars in developing
regions is proving to be an efficient drug which has resulted in the growth of the
market. The rising number of clinical trials for the combined therapies is boosting the
growth of the market as well. New drug formulations are currently in the processing
stages of different phases of clinical development and this has augured the growth of
the market.
A huge trend recognised in the triple-negative breast cancer treatment is the
evolution of nanotechnology. Nanotechnology has emerged as an efficient tool in the
clinical management of triple-negative breast cancer.
North America currently holds a vast share of the market. The presence of prominent
players alongside advanced healthcare infrastructure has expanded the size of the
market. The Asia Pacific and Latin America regions have established vast potential
opportunistic space for manufacturers thanks to an increase in treatment rate and
rising prevalence of triple-negative breast.
Established players of the market are Sanofi S.A, Bristol-Myers Squibb Company,
Johnson & Johnson Services, Inc., Eli Lilly and Company, Mylan N.V and Novartis
AG.
Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=249&page=requestsample
Global Triple-Negative Breast Cancer Treatment Market Segmentation:
By Drug Type:
• Doxorubicin
• Cyclophosphamide
• Paclitaxel
• Docetaxel
• Cisplatin/Carboplatin
• Others
By Distribution Channel
• Hospital Pharmacies
• Specialty Cancer Clinics
By Region:
• Europe
• North America
• APAC
• Latin America
• Rest of World
Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/requestsample.aspx?id=249&page=askfordiscount
FutureWise Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on Global Triple-Negative Breast Cancer
Treatment Market by Drug Type, by Distribution Channel, by Region
• To cater comprehensive information on factors impacting market growth (drivers,
restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America,
Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches,
technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and
core competencies
Table of Contents
1. Market Introduction


Market Definition
Market Taxonomy
2. Executive Summary


Market Overview
Market Analysis
3. Market Dynamics



Drivers
Restraints
Trends
4. Historical Market Size (US$ Mn) By Drug Type, 2014-2018







Doxorubicin
Cyclophosphamide
Paclitaxel
Docetaxel
Carboplatin/Cisplatin
Others
Market Size (US$ Mn) Forecast By Drug Type, 2019–2029
5. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 20142018



Hospital Pharmacies
Specialty Cancer Clinics
Market Size (US$ Mn) and Forecast By Distribution Channel, 2019–2029
6. North America Triple-Negative Breast Cancer Treatment Market Analysis 20142018 and Forecast 2019–2029





Introduction
Historical Market Size (US$ Mn) & Analysis By Country, 2014-2018
U.S.
Canada
Market Size (US$ Mn) & Forecast By Country, 2019–2029
7. Latin America Triple-Negative Breast Cancer Treatment Market Analysis 20142018and Forecast 2019–2029






Introduction
Historical Market Size (US$ Mn) Trends and Analysis By Country, 2014-2018
Brazil
Mexico
Rest of Latin America
Market Size (US$ Mn) & Forecast By Country, 2019–2029
8. Europe Triple-Negative Breast Cancer Treatment Market Analysis 2014-2018and
Forecast 2019–2029











Introduction
Regional Trends
Historical Market Size (US$ Mn) and Trend Analysis By Country, 2014-2018
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Market Size (US$ Mn) & Forecast By Country, 2019–2029
9. Asia Pacific Excluding China Triple-Negative Breast Cancer Treatment Market
Analysis 2014-2018 and Forecast 2019–2029








Introduction
Historical Market Size (US$ Mn) Trend Analysis By Country, 2014-2018
China
India
Australia
Japan
ASEAN
Rest of Asia Pacific

Market Size (US$ Mn) & Forecast By Country, 2019–2029
10. Middle East & Africa Triple-Negative Breast Cancer Treatment Market Analysis
2014-2018and Forecast 2019–2029






Introduction
Historical Market Size (US$ Mn) and Trend Analysis By Country, 2014-2018
GCC Countries
South Africa
Rest of MEA
Market Size (US$ Mn) & Forecast By Country, 2019–2029
11. Competition Analysis










AstraZeneca PLC
Pfizer, Inc.
F. Hoffman - La Roche Ltd.
Bristol-Myers Squibb Company
Novartis AG
Mylan N.V.
Eli Lilly and Company
Celgene Corporation
Sanofi S.A.
Johnson & Johnson Services, Inc.
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and
customised solutions for our clients. Through in-depth market insights and
consultancy, we present our clients with the tools they need to be at the forefront of
their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
1/--pages
Report inappropriate content